Drug profile · INN
crizanlizumab-tmca
ADAKVEO
crizanlizumab-tmca (ADAKVEO) is a p-selectin blocker. Route of administration: injection. Current US regulatory status: approved.
Drug details — crizanlizumab-tmca
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
crizanlizumab-tmca (ADAKVEO) is a p-selectin blocker. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
P-selectin blocker
Primary target: P-selectin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is crizanlizumab-tmca?
crizanlizumab-tmca (ADAKVEO) is a p-selectin blocker. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for crizanlizumab-tmca?
ADAKVEO is a marketed brand name for crizanlizumab-tmca. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of crizanlizumab-tmca?
crizanlizumab-tmca has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.